Therapeutic Asset Ratings

183 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Isatuximab Acute Lymphoblastic Leukemia	Assistance Publique - Hôpitaux de Paris	P2/3	CCC (54)
Vedolizumab Acute Lymphoblastic Leukemia	City of Hope Medical Center	P3	CCC (53)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Acute Lymphoblastic Leukemia	David Wald	P1/2	CCC (53)
Levoleucovorin Acute Lymphoblastic Leukemia	Children's Oncology Group	P3	CCC (52)
aciclovir Acute Lymphoblastic Leukemia	City of Hope Medical Center	P2	CCC (52)
Letermovir Acute Lymphoblastic Leukemia	City of Hope Medical Center	P2	CCC (52)
Pcar-19B Cells Acute Lymphoblastic Leukemia	Chongqing Precision Biotech Co., Ltd	P2	CCC (52)
Ruxolitinib Phosphate Acute Lymphoblastic Leukemia	City of Hope Medical Center	P2	CCC (52)
Zoledronate Acute Lymphoblastic Leukemia	Children's Hospital of Eastern Ontario	P2	CCC (52)
Decitabine Acute Lymphoblastic Leukemia	Princess Maxima Center for Pediatric Oncology	P1/2	CCC (52)
Flumatinib Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Keppra Acute Lymphoblastic Leukemia	Center for International Blood and Marrow Transplant Research	P2	CCC (51)
Palifermin Acute Lymphoblastic Leukemia	Center for International Blood and Marrow Transplant Research	P2	CCC (51)
Siltuximab Acute Lymphoblastic Leukemia	University of Alabama at Birmingham	P2	CCC (51)
Baricitinib Acute Lymphoblastic Leukemia	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	P2/3	CCC (50)
Omacetaxine Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2/3	CCC (50)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Acute Lymphoblastic Leukemia	Fred Hutchinson Cancer Center	P2	CCC (48)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Axicabtagene Ciloleucel Acute Lymphoblastic Leukemia	Novartis Pharmaceuticals	P2	CCC (48)
BEBT 908 Acute Lymphoblastic Leukemia	Ruijin Hospital	P2	CCC (48)
Brexucabtagene Autoleucel Acute Lymphoblastic Leukemia	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (48)
Breyanzi Injectable Product Acute Lymphoblastic Leukemia	Masonic Cancer Center, University of Minnesota	P2	CCC (48)
Calaspargase Acute Lymphoblastic Leukemia	St. Jude Children's Research Hospital	P2	CCC (48)
Docetaxel Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (48)
Epirubicin Acute Lymphoblastic Leukemia	National Hospital Organization Nagoya Medical Center	P2	CCC (48)

Showing 76 to 100 of 183 assets

PreviousPage 4 of 8Next